Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome

British Journal of Ophthalmology

Volumn 83, Issue 10, 1999, Pages 1121-1124

  Condon, Patrick I ^a   McEwen, Charles G ^b   Wright, Mark ^c   Mackintosh, Graeme ^d   Prescott, Robin J ^e   McDonald, Carolyn ^f  

^a WATERFORD REGIONAL HOSPITAL   (Ireland)

^b Princess Alexandra Eye Pavilion ^*  (United Kingdom)

^c PRINCESS ALEXANDRA EYE PAVILION   (United Kingdom)

^d GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f Heriot Watt Research Park   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FERMAVISC; HYALURONIC ACID; ROSE BENGAL; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; SYMPTOM; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0032883643     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.83.10.1121     Document Type: Article

References (18)

1. Balazs EA, Armand G. Gylcosaminoglycans and proteoglycans of ocular tissues. In: Varma RS, Varma R, eds. Glycosaminoglycans and proteoglycans in physiological and pathological processes of body systems. Basle: Karger, 1982:480-9.
2. DeLuise VF, Peterson WS. The use of topical Healon tears in the management of refractory dry-eye syndrome. Ann Ophthalmol 1984:823-4.
3. Polack FM, McNiece MT. The treatment of dry eyes with Na hyaluronate (Healon). Cornea 1982;1:133-6.
4. Sand BB, Marner K, Norn MS, Sodium hyaluronate in the treatment of keratoconjunctivitis sicca. Acta Ophthalmol 1989;67:181-3.
5. Stuart JC, Linn JG. Dilute sodium hyaluronate (Healon) in the treatment of ocular surface disorders. Ann Ophthalmol 1985;17:190-2.
6. Wysenbeek WS, Loya N, Sira BI, et al. The effect of sodium on the corneal epithelium. Invest Ophthalmol Vis Sci 1988;29:194-9.
7. Van Bijstenweld OP. Diagnostic tests in the sicca syndrome. Arch Ophthalmol 1969;82:10-14.
8. Hills M, Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol 1979;8:7-20.
9. Prescott RJ. The comparison of success rates in cross-over trials in the presence of an order effect. Appl Stat 1981;30:9-15.
10. Fukuda M, Miyamoto Y, Miyara Y, et al. Hyaluronic acid in tear fluid and its synthesis by corneal epithelial cells. Asia-Pacific J Ophthalmol 1998;10:20-2.
11. Mengher LS, Pandher KS, Bron AJ, et al. Effect of sodium hyaluronate (0.1%) on break-up time (NIBUT) in patients with dry eyes, Br J Ophthalmol 1986;70:442-7.
12. Hamano T, Horimoto K, Lee M, et al. Sodium hyaluronate eyedrops enhance tear film stability. Jpn J Ophthalmol 1996;40:62-5.
13. Yokoi N, Komuro A, Nishida K, et al. Effectiveness of hyaluronan on corneal epithelial barrier function in dry eye. Br J Ophthalmol 1997;81:533-6.
14. Shimmura S, Ono M, Shinozaki K, et al. Sodium hyaluronate eye drops in the treatment of dry eyes. Br J Ophthalmol 1995;19:1007-11.
15. Nishida T, Nakamura M, Mishima H, et al. Hyaluronan stimulates corneal epithelial migration. Exp Eye Res 1991;53:753-8.
16. Ke-Ping X, Yukiko Y, Tsubota K. Decrease in corneal sensitivity and change in tear function in dry eye. Cornea 1996;15:235-9.
17. Nakamura M, Hikida M, Nakano T, et al. Characterization of water retentive properties of hyaluronan. Cornea 1993;12:433-6.
18. Tsubota K, Yamada M. Tear evaporation from the ocular surface. Invest Ophthalmol Vis Sci 1992;33:2942-50.